Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches

mAbs

Volumn 5, Issue 4, 2013, Pages 565-575

  Li, Chen ^a   Rossomando, Anthony ^b,c   Wu, Shiaw Lin ^a   Karger, Barry L ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b ALNYLAM PHARMACEUTICALS   (United States)

^c Synageva BioPharma Corp   (United States)

Author keywords

Biosimilar; Disulfide scrambling; Free cysteine; LC MS; Sequence mutation; Structure characterization

Indexed keywords

ASPARAGINE; CYSTEINE; FC RECEPTOR; FUCOSE; METHIONINE; PEPSIN A; RITUXIMAB;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMICAL LABELING; CONTROLLED STUDY; DEAMINATION; DISULFIDE BOND; DRUG STRUCTURE; FUCOSYLATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MUTATION; OXIDATION; PH; PROTEIN MODIFICATION; RNA INTERFERENCE;

BIOSIMILAR; DISULFIDE SCRAMBLING; FREE CYSTEINE; LC-MS; SEQUENCE MUTATION; STRUCTURE CHARACTERIZATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FUCOSE; GLYCOSYLATION; HUMANS; MASS SPECTROMETRY; POINT MUTATION; PROTEIN ENGINEERING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE;

EID: 84880102955     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.24814     Document Type: Article

References (35)

1. Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr., Bearden JD 3rd, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95:3052-6; PMID:10807768
2. Okamoto H, Kamatani N. Rituximab for rheumatoid arthritis. N Engl J Med 2004; 351:1909, author reply 1909; PMID:15509828; http://dx.doi.org/10.1056/ NEJM200410283511820
3. Taylor PC. Rituximab in the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2007; 3:17-26; PMID:20476947; http://dx.doi.org/10.1586/1744666X. 3.1.17
4. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000; 204:55-63; PMID:11006018; http://dx.doi.org/10.1006/cimm.2000.1693
5. Harjunpää A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51:634-41; PMID:10849376; http://dx.doi.org/10.1046/j.1365-3083.2000.00745.x
6. Rodriguez J, Gutierrez A. Pharmacokinetic properties of rituximab. Rev Recent Clin Trials 2008; 3:22-30; PMID:18474012; http://dx.doi.org/10.2174/ 157488708783330495
7. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200
8. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64:2127-33; PMID:15026353; http://dx.doi.org/10.1158/0008-5472.CAN-03-2068
9. Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004; 10:6248-55; PMID:15448014; http://dx.doi.org/10.1158/1078-0432.CCR-04-0850
10. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11:2327-36; PMID:15788684; http://dx.doi.org/10.1158/1078-0432.CCR-04-2263
11. Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005; 306:151-60; PMID:16219319; http://dx.doi.org/10.1016/j.jim.2005.08.009
12. Tummala S, Titus M, Wilson L, Wang C, Ciatto C, Foster D, et al. Evaluation of exogenous siRNA addition as a metabolic engineering tool for modifying biopharmaceuticals. Biotechnol Prog 2012; In press; PMID:23172735.
13. Anderson DR, Hanna N, Leonard GE, Newman RA, Reff ME, Rastetter WH. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma 1998. US patent 5736137.
14. Manuilov AV, Radziejewski CH, Lee DH. Comparability analysis of protein therapeutics by bottom-up LC-MS with stable isotope-tagged reference standards. MAbs 2011; 3:387-95; PMID:21654206; http://dx.doi.org/10.4161/mabs.3.4.16237
15. Sousa E, Olland S, Shih HH, Marquette K, Martone R, Lu Z, et al. Primary sequence determination of a monoclonal antibody against α-synuclein using a novel mass spectrometry-based approach. Int J Mass Spectrom 2012; 312:61-9; http://dx.doi.org/10.1016/j.ijms.2011.05.005
16. Boersema PJ, Raijmakers R, Lemeer S, Mohammed S, Heck AJ. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat Protoc 2009; 4:484-94; PMID:19300442; http://dx.doi.org/10.1038/nprot.2009.21
17. Ni W, Lin M, Salinas P, Savickas P, Wu SL, Karger BL. Complete mapping of a cystine knot and nested disulfides of recombinant human arylsulfatase A by multi-enzyme digestion and LC-MS analysis using CID and ETD. J Am Soc Mass Spectrom 2013; 24:125-33; PMID:23208745; http://dx.doi.org/10.1007/s13361-012- 0510-z
18. Brych SR, Gokarn YR, Hultgen H, Stevenson RJ, Rajan R, Matsumura M. Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation. J Pharm Sci 2010; 99:764-81; PMID:19691118
19. Symes AL, Sourkes TL. Essential sulfhydryl groups of rat liver monoamine oxidase. Can J Biochem 1975; 53:910-3; PMID:1181010; http://dx.doi.org/10.1139/ o75-125
20. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70-7; PMID:13650640; http://dx.doi.org/10.1016/0003-9861(59)90090-6
21. Riener CK, Kada G, Gruber HJ. Quick measurement of protein sulfhydryls with Ellman's reagent and with 4,4′-dithiodipyridine. Anal Bioanal Chem 2002; 373:266-76; PMID:12110978; http://dx.doi.org/10.1007/s00216-002-1347-2
22. Chumsae C, Gaza-Bulseco G, Liu H. Identification and localization of unpaired cysteine residues in monoclonal antibodies by fluorescence labeling and mass spectrometry. Anal Chem 2009; 81:6449-57; PMID:19572546; http://dx.doi.org/10.1021/ac900815z
23. Xiang T, Chumsae C, Liu H. Localization and quantitation of free sulfhydryl in recombinant monoclonal antibodies by differential labeling with 12C and 13C iodoacetic acid and LC-MS analysis. Anal Chem 2009; 81:8101-8; PMID:19722496; http://dx.doi.org/10.1021/ac901311y
24. Zhang W, Czupryn MJ. Free sulfhydryl in recombinant monoclonal antibodies. Biotechnol Prog 2002; 18:509-13; PMID:12052067; http://dx.doi.org/ 10.1021/bp025511z
25. Harris RJ. Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol (Basel) 2005; 122:117-27; PMID:16375256
26. Schauenstein E, Sorger S, Reiter M, Dachs F. Free thiol groups and labile disulfide bonds in the IgG fraction of human serum. J Immunol Methods 1982; 50:51-6; PMID:7086149; http://dx.doi.org/10.1016/0022-1759(82)90303-9
27. Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J Immunol 2003; 170:3134-8; PMID:12626570
28. Gevondyan NM, Volynskaia AM, Gevondyan VS. Four free cysteine residues found in human IgG1 of healthy donors. Biochemistry (Mosc) 2006; 71:279-84; PMID:16545064; http://dx.doi.org/10.1134/S0006297906030072
29. Kelleher NL, Lin HY, Valaskovic GA, Aaserud DJ, Fridriksson EK, McLafferty FW. Top down versus bottom up protein characterization by tandem high-resolution mass spectrometry. J Am Chem Soc 1999; 121:806-12; http://dx.doi.org/10.1021/ja973655h
30. Chait BT. Chemistry. Mass spectrometry: bottom-up or top-down? Science 2006; 314:65-6; PMID:17023639; http://dx.doi.org/10.1126/science.1133987
31. Zamdborg L, LeDuc RD, Glowacz KJ, Kim YB, Viswanathan V, Spaulding IT, et al. ProSight PTM 2.0: improved protein identification and characterization for top down mass spectrometry. Nucleic Acids Res 2007; 35(Web Server issue):W701-6; PMID:17586823; http://dx.doi.org/10.1093/nar/gkm371
32. Fornelli L, Damoc E, Thomas PM, Kelleher NL, Aizikov K, Denisov E, et al. Analysis of intact monoclonal antibody IgG1 by electron transfer dissociation Orbitrap FTMS. Mol Cell Proteomics 2012; 11:1758-67; PMID:22964222; http://dx.doi.org/10.1074/mcp.M112.019620
33. Wu SL, Kim J, Hancock WS, Karger B. Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS platform for high sequence coverage of complex proteins with extensive post-translational modifications-comprehensive analysis of beta-casein and epidermal growth factor receptor (EGFR). J Proteome Res 2005; 4:1155-70; PMID:16083266; http://dx.doi.org/10.1021/pr050113n
34. Wu SL, Kim J, Bandle RW, Liotta L, Petricoin E, Karger BL. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). Mol Cell Proteomics 2006; 5:1610-27; PMID:16799092; http://dx.doi.org/10.1074/mcp.M600105-MCP200
35. Pipes GD, Campbell P, Bondarenko PV, Kerwin BA, Treuheit MJ, Gadgil HS. Middle-down fragmentation for the identification and quantitation of site-specific methionine oxidation in an IgG1 molecule. J Pharm Sci 2010; 99:4469-76; PMID:20845446; http://dx.doi.org/10.1002/jps.22158